Abveris specializes in advanced antibody discovery technologies, prominently featuring its proprietary DiversimAb™ platform. This innovative platform utilizes hyperimmune mouse models to generate a diverse array of antibodies, particularly against challenging targets such as G protein-coupled receptors (GPCRs) and other difficult-to-immunize proteins. The DiversimAb™ technology enhances the immune response, allowing for the production of high-affinity antibodies that can be tailored for therapeutic and reagent applications. Abveris employs a comprehensive, end-to-end approach to antibody discovery, which includes repertoire generation, advanced screening, characterization, and humanization processes, ensuring that clients receive robust and effective antibody candidates.

In addition to the DiversimAb™ platform, Abveris integrates various state-of-the-art technologies such as high-throughput single B-cell screening and hybridoma-based production methods. The company utilizes tools like the Berkeley Lights Beacon for rapid screening and characterization of antibody candidates, as well as Octet BLI and Carterra SPR for kinetic and epitope binning analyses. This combination of advanced technologies and methodologies positions Abveris as a leader in the field of antibody discovery, enabling biopharma partners to efficiently develop high-quality antibodies for a wide range of therapeutic applications.

United States

Abveris is a world leader in in vivo antibody discovery and a division of Twist Bioscience. We partner with leading biopharmaceutical scientists across diverse organizations to discover and develop antibodies for diverse pharmaceutical and industrial applications.

Abveris

Company Details